DK0985039T3 - Kunstige antistof-polypeptider - Google Patents

Kunstige antistof-polypeptider

Info

Publication number
DK0985039T3
DK0985039T3 DK98930131T DK98930131T DK0985039T3 DK 0985039 T3 DK0985039 T3 DK 0985039T3 DK 98930131 T DK98930131 T DK 98930131T DK 98930131 T DK98930131 T DK 98930131T DK 0985039 T3 DK0985039 T3 DK 0985039T3
Authority
DK
Denmark
Prior art keywords
polypeptide
monobody
uncat
cat
identifying
Prior art date
Application number
DK98930131T
Other languages
English (en)
Inventor
Shohei Koide
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Application granted granted Critical
Publication of DK0985039T3 publication Critical patent/DK0985039T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK98930131T 1997-06-12 1998-06-12 Kunstige antistof-polypeptider DK0985039T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4941097P 1997-06-12 1997-06-12
PCT/US1998/012099 WO1998056915A2 (en) 1997-06-12 1998-06-12 Artificial antibody polypeptides

Publications (1)

Publication Number Publication Date
DK0985039T3 true DK0985039T3 (da) 2008-06-09

Family

ID=21959681

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98930131T DK0985039T3 (da) 1997-06-12 1998-06-12 Kunstige antistof-polypeptider

Country Status (10)

Country Link
US (11) US6673901B2 (da)
EP (3) EP1958962A3 (da)
JP (1) JP3614866B2 (da)
AT (1) ATE386802T1 (da)
AU (1) AU729035B2 (da)
CA (1) CA2293632C (da)
DE (1) DE69839147T2 (da)
DK (1) DK0985039T3 (da)
ES (1) ES2301198T3 (da)
WO (1) WO1998056915A2 (da)

Families Citing this family (636)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
AUPP221098A0 (en) * 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
DE69933044T3 (de) * 1998-11-27 2016-11-24 Ucb Pharma, S.A. Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
DE69941267D1 (de) * 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) * 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DE19932688B4 (de) * 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
CA2416219C (en) * 2000-07-11 2016-10-11 Research Corporation Technologies, Inc. Artificial antibody polypeptides
CA2418835A1 (en) * 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7598352B2 (en) 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
CA2443332A1 (en) 2001-04-04 2002-10-17 University Of Rochester .alpha..nu..beta.3 integrin-binding polypeptide monobodies and their use
EP1318195A1 (en) * 2001-12-10 2003-06-11 CatchMabs B.V. A structure for presenting desired peptide sequences
US20050037427A1 (en) * 2001-12-10 2005-02-17 Erwin Houtzager Structure for presenting desired peptide sequences
US20030215914A1 (en) * 2001-12-10 2003-11-20 Erwin Houtzager Structure for presenting desired peptide sequences
CN1639185A (zh) * 2002-01-03 2005-07-13 斯克里普斯研究学院 癌相关表位
AU2003209272A1 (en) * 2002-01-16 2003-09-02 Zyomyx, Inc. Engineered binding proteins
US6936427B2 (en) * 2002-02-08 2005-08-30 Trellis Bioscience, Inc. Real time detection of intermolecular interaction
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
WO2003104418A2 (en) * 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
JP2005530515A (ja) * 2002-06-26 2005-10-13 ユニヴァーシティー オヴ ルイスヴィル リサーチ ファウンデイション インコーポレイテッド アポトーシスの検出方法
US20050074865A1 (en) 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
US7083948B1 (en) 2002-12-24 2006-08-01 Immunex Corporation Polypeptide purification reagents and methods for their use
US7196715B2 (en) * 2003-01-17 2007-03-27 Hewlett-Packard Development Company, L.P. Speed control using drive current profile
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DE10324447A1 (de) * 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
EP1636270B1 (en) * 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US20040266993A1 (en) * 2003-06-30 2004-12-30 Evans Glen A. Non-immunoglobulin binding polypeptides
BRPI0414093A (pt) * 2003-09-05 2006-10-31 Scripps Res Insittute produtos de ozonização de colesterol para o tratamento e prevenção de ateroesclerose e/ou doenças cardiovasculares
WO2005023831A1 (en) * 2003-09-05 2005-03-17 The Scripps Research Institute Detection of cholesterol ozonation products
CN1946417A (zh) * 2003-12-05 2007-04-11 阿德内克休斯治疗公司 2型血管内皮生长因子受体的抑制剂
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
ES2297673T3 (es) * 2004-03-03 2008-05-01 F. Hoffmann-La Roche Ag Metodo para la purificacion de un fragmento n-terminal del factor de crecimiento de hepatocitos.
US7604947B2 (en) * 2004-06-09 2009-10-20 Cornell Research Foundation, Inc. Detection and modulation of cancer stem cells
DE102004049479A1 (de) * 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
CN103555733A (zh) 2005-01-05 2014-02-05 F-星生物技术研究与开发有限公司 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域
ITMI20050739A1 (it) * 2005-04-22 2006-10-23 Effebi Spa Piastrina di connsessione valvola-attuatore
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US20110143953A1 (en) * 2006-10-16 2011-06-16 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Synthetic Antibodies
CN101588816B (zh) 2006-10-19 2013-06-19 Csl有限公司 白介素-13受体α1的高亲和性抗体拮抗物
WO2008133722A2 (en) * 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
EP1925664A1 (en) * 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
IN2009DN05758A (da) * 2007-03-12 2015-07-24 Esbatech Ag
KR101530723B1 (ko) * 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
US20090074780A1 (en) 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
EP3241842B1 (en) 2007-06-26 2024-01-31 F-star Therapeutics Limited Display of binding agents
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
EP2215246B1 (en) 2007-10-31 2015-01-07 MedImmune, LLC Protein scaffolds
KR20100091170A (ko) 2007-11-02 2010-08-18 노파르티스 아게 저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법
WO2009062170A1 (en) 2007-11-08 2009-05-14 The University Of Chicago Molecular affinity clamp technology and uses thereof
DK2207568T3 (da) 2007-11-16 2017-09-18 Univ Rockefeller Antistoffer specifikke for den protofibrile form af beta-amyloid-protein
US20110044978A1 (en) * 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
WO2009078799A1 (en) 2007-12-17 2009-06-25 Marfl Ab New vaccine for the treatment of mycobacterium related disorders
WO2009088837A2 (en) * 2007-12-31 2009-07-16 The University Of Louisville Research Foundation, Inc. Methods and products to target, capture and characterize stem cells
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
WO2009126031A1 (en) * 2008-04-10 2009-10-15 Fujifilm Manufacturing Europe B.V. Recombinant protein enriched in a heparin binding site and/or a heparan sulfate binding site
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
PL2274331T3 (pl) * 2008-05-02 2014-04-30 Novartis Ag Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
PL3241843T3 (pl) 2008-06-25 2021-12-27 Novartis Ag Optymalizacja rozpuszczalności cząsteczek immunowiążących
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
US9433684B2 (en) 2008-08-19 2016-09-06 Nektar Therapeutics Conjugates of small-interfering nucleic acids
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
BRPI0919881B1 (pt) 2008-10-31 2021-09-08 Centocor Ortho Biotech Inc Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US20110275535A1 (en) 2008-12-16 2011-11-10 Novartis Ag Yeast Display Systems
BRPI1008532B1 (pt) * 2009-02-12 2021-12-14 Janssen Biotech, Inc Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
US8067201B2 (en) * 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
EP2464657B1 (en) 2009-08-10 2015-04-01 MorphoSys AG Novel screening strategies for the identification of antibodies or fragments thereof which bind an antigen that has an enzymatic activity
EP2494046B1 (en) 2009-10-30 2018-09-12 Novartis AG Universal fibronectin type iii bottom-side binding domain libraries
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
DE102009047243A1 (de) 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
AU2010332932B2 (en) 2009-12-14 2013-01-17 Navigo Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin
WO2011075636A2 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
WO2012091756A1 (en) 2010-12-30 2012-07-05 Avidbiotics Corp. Non-natural mic proteins
EP2528944B1 (en) 2010-01-29 2015-08-12 MorphoSys AG Rodent combinatorial antibody libraries
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
WO2011100700A2 (en) * 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
US8551715B2 (en) 2010-02-12 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
CA2795325A1 (en) 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
EA022983B1 (ru) * 2010-04-13 2016-04-29 Бристол-Майерс Сквибб Компани Белки на основе структурного домена фибронектина, связывающие pcsk9
AU2011239935A1 (en) 2010-04-16 2012-11-08 Novartis Ag Methods and compositions for improving implant osseointegration
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
EP3569256B1 (en) 2010-04-30 2022-06-15 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
CN103096912A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103140233B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP4234698A3 (en) 2010-05-06 2023-11-08 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
KR20130066631A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
ES2816898T3 (es) 2010-05-13 2021-04-06 Sarepta Therapeutics Inc Compuestos que modulan la actividad de señalización de las interleucinas 17 y 23
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
CN103096914B (zh) 2010-05-17 2015-08-12 Atyr医药公司 与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
ES2573108T3 (es) 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada
CA2800375C (en) 2010-05-27 2021-03-09 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
SG10201505217WA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
EP2593125B1 (en) 2010-07-12 2017-11-01 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
JP5809687B2 (ja) 2010-07-14 2015-11-11 ジーンフロンティア株式会社 Ｒｎｆ８−ｆｈａドメイン改変タンパク質及びその製造方法
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
CN107903321A (zh) 2010-07-30 2018-04-13 诺华有限公司 纤连蛋白摇篮分子和其库
NZ607337A (en) 2010-08-20 2015-06-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
WO2012054870A2 (en) 2010-10-21 2012-04-26 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
WO2012084272A1 (en) 2010-12-23 2012-06-28 Intercell Ag Oprf/i agents and their use in hospitalized and other patients
EP2681242B1 (en) 2011-03-01 2018-01-24 Amgen Inc. Sclerostin and dkk-1 bispecific binding agents
WO2012135035A1 (en) 2011-03-25 2012-10-04 Amgen Inc. Anti - sclerostin antibody crystals and formulations thereof
RS55609B1 (sr) 2011-04-13 2017-06-30 Bristol Myers Squibb Co Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
ES2685479T3 (es) 2011-04-19 2018-10-09 Amgen Inc. Método para el tratamiento de la osteoporosis
EP2702408A1 (en) 2011-04-29 2014-03-05 Novartis AG Methods of treating squamous cell carcinoma related applications
EP3318880B1 (en) 2011-05-17 2020-12-16 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
EP2709669A1 (en) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
ES2572915T3 (es) 2011-06-02 2016-06-03 The University Of Louisville Research Foundation, Inc. Nanopartículas conjugadas a un agente antinucleolina
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
JP6146821B2 (ja) 2011-06-15 2017-06-14 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 修飾ユビキチンに基づく二量体型結合タンパク質
CA2842432C (en) 2011-08-04 2022-10-04 Amgen Inc. Method for treating bone gap defects
EP2761066B1 (en) 2011-09-27 2018-12-05 Janssen Biotech, Inc. Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
AU2012323316B2 (en) 2011-10-11 2017-08-10 Viela Bio, Inc. CD40L-specific Tn3-derived scaffolds and methods of use thereof
CN109111523B (zh) 2011-10-14 2022-06-07 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
US20140283153A1 (en) * 2011-10-28 2014-09-18 Trianni, Inc. Transgenic animals and methods of use
EP2773659A2 (en) 2011-10-31 2014-09-10 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
CA2854806A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
KR20140103135A (ko) 2011-12-05 2014-08-25 노파르티스 아게 Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
PE20150159A1 (es) 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p
SG11201403718YA (en) 2011-12-28 2014-07-30 Amgen Inc Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
MX350378B (es) 2012-01-10 2017-09-05 Biogen Ma Inc Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica.
MX356107B (es) 2012-02-16 2018-05-15 Atyr Pharma Inc Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
EP2830659A1 (en) 2012-03-27 2015-02-04 Novartis AG Treatment of fibrosis
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
EP2657334B1 (en) 2012-04-26 2016-07-06 GeneFrontier Corporation Efficient method for displaying protein multimer
WO2013169734A1 (en) 2012-05-07 2013-11-14 Amgen Inc. Anti-erythropoietin antibodies
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
EP2855520B1 (en) 2012-06-04 2018-09-26 Novartis AG Site-specific labeling methods and molecules produced thereby
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
US9925260B2 (en) 2012-07-05 2018-03-27 Ucb Pharma S.A. Treatment for bone diseases
WO2014015217A1 (en) 2012-07-19 2014-01-23 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
WO2014039775A1 (en) 2012-09-07 2014-03-13 Rutgers, The State University Of New Jersey Hiv-1 antigens with discrete conformational forms of the v1/v2 domain and methods of use thereof
TWI633117B (zh) 2012-09-13 2018-08-21 必治妥美雅史谷比公司 結合至肌肉生長抑制素（ｍｙｏｓｔａｔｉｎ）以纖維連接蛋白爲主之支架結構域蛋白質
US9671405B2 (en) 2012-09-19 2017-06-06 Cornell University Identifying taxane sensitivity in prostate cancer patients
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
CN113201073A (zh) 2012-11-21 2021-08-03 詹森生物科技公司 双特异性EGFR/c-Met抗体
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
HUE053669T2 (hu) 2012-12-05 2021-07-28 Novartis Ag Készítmények és eljárások EPO-t célzó antitestekre
EP2935589A1 (en) 2012-12-18 2015-10-28 Novartis AG Compositions and methods that utilize a peptide tag that binds to hyaluronan
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
EP2951206A2 (en) 2013-02-01 2015-12-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
SG10201706148WA (en) 2013-02-01 2017-08-30 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
ES2689372T3 (es) 2013-02-06 2018-11-13 Bristol-Myers Squibb Company Proteínas de dominio de fibronectina tipo III con solubilidad mejorada
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
KR102447350B1 (ko) 2013-02-08 2022-09-23 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
ES2870802T3 (es) 2013-02-12 2021-10-27 Bristol Myers Squibb Co Métodos de replegado de proteínas a elevado pH
AU2014249458A1 (en) 2013-03-11 2015-09-24 Amgen Inc. Protein formulations
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
NZ710929A (en) 2013-03-15 2018-02-23 Novartis Ag Antibody drug conjugates
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
CN105899226B (zh) 2013-10-14 2020-05-12 詹森生物科技公司 半胱氨酸工程化iii型纤连蛋白域结合分子
WO2015073878A1 (en) 2013-11-15 2015-05-21 Ur Diet, Llc Real-time satiety biofeedback
CN109917125A (zh) 2013-12-03 2019-06-21 哈佛大学董事会 用于评估妊娠糖尿病的方法和试剂
CN103698175B (zh) * 2013-12-09 2016-06-22 成都欧林生物科技股份有限公司 金黄色葡萄球菌疫苗成品的解离及含量测定方法和检测试剂盒
MX2016007533A (es) 2013-12-09 2016-12-14 Univ New York Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos.
BR112016012538A2 (pt) 2013-12-17 2017-09-26 Novartis Ag peptídeos citotóxicos e conjugados dos mesmos
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
US20150174242A1 (en) 2013-12-19 2015-06-25 Mayo Foundation For Medical Education And Research Monovalent anti-cd3 adjuvants
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
US11028143B2 (en) 2014-01-21 2021-06-08 Novartis Ag Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
US20170073754A1 (en) 2014-02-07 2017-03-16 Novartis Ag Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
CA2940451A1 (en) 2014-03-12 2015-09-17 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
EP3129401B1 (en) 2014-03-20 2019-06-12 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type iii domains
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
US10590485B2 (en) 2014-05-29 2020-03-17 Geneticure Llc Therapeutic regimen for hypertension
AU2015274482B2 (en) 2014-06-12 2018-11-08 Ucb Holdings, Inc. Modulation of complement activity
CN106573956A (zh) 2014-06-13 2017-04-19 诺华股份有限公司 澳瑞他汀衍生物及其缀合物
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
CA2952609A1 (en) 2014-06-26 2015-12-30 Amgen Inc. Solid protein formulations comprising stabilizer, sugar alcohol, sugar and surfactant
CA2954476C (en) 2014-07-10 2023-09-19 Novartis Ag Immune-stimulating monoclonal antibodies against human interleukin-2
WO2016011167A1 (en) 2014-07-16 2016-01-21 Dana-Farber Cancer Institute, Inc., Et Al Her3 inhibition in low-grade serous ovarian cancers
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
US10690669B2 (en) 2014-08-01 2020-06-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Bovine herpesvirus detection and treatment
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
WO2016020880A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
KR20170040249A (ko) 2014-08-12 2017-04-12 노파르티스 아게 항-cdh6 항체 약물 접합체
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
EP3191592A1 (en) 2014-09-11 2017-07-19 Novartis AG Inhibition of prmt5 to treat mtap-deficiency-related diseases
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
EP3215519A1 (en) 2014-11-06 2017-09-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
IL313511A (en) 2014-11-12 2024-08-01 Seagen Inc Compounds acting on glycans and methods of using them
WO2016075670A1 (en) 2014-11-14 2016-05-19 Novartis Ag Antibody drug conjugates
EP3227446A1 (en) 2014-12-01 2017-10-11 Novartis AG Compositions and methods for diagnosis and treatment of prostate cancer
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
CN111018987B (zh) 2014-12-05 2023-11-21 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其应用
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
CA3197849A1 (en) 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3250230B9 (en) 2015-01-28 2022-02-23 RA Pharmaceuticals, Inc. Modulators of complement activity
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
EP3842451A1 (en) 2015-03-12 2021-06-30 MedImmune, LLC Method of purifying albumin-fusion proteins
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
SG11201708516YA (en) 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CA3020885A1 (en) 2015-05-05 2016-11-10 Mohammad Tariq MALIK Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
EP3292222B1 (en) 2015-05-06 2025-09-03 Janssen Biotech, Inc. Prostate specific membrane antigen binding fibronectin type iii domains
WO2016197071A1 (en) 2015-06-05 2016-12-08 New York University Compositions and methods for anti-staphylococcal biologic agents
EP3302525A2 (en) 2015-06-05 2018-04-11 Novartis AG Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
CA2982237A1 (en) 2015-06-05 2016-12-08 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
EP3310813A1 (en) 2015-06-17 2018-04-25 Novartis AG Antibody drug conjugates
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
AU2016293063B2 (en) 2015-07-16 2018-11-08 Navigo Proteins Gmbh Novel immunoglobulin-binding proteins and their use in affinity purification
JP7105186B2 (ja) 2015-07-17 2022-07-22 ザ・ユニバーシティ・オブ・シカゴ 酵素を修飾するための方法および組成物
JP2018520675A (ja) 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
CA3185706C (en) 2015-08-03 2025-11-18 Novartis Ag METHOD FOR TREATMENT OF DISORDERS ASSOCIATED WITH FGF21
JP6905163B2 (ja) 2015-09-03 2021-07-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア サイトカイン放出症候群を予測するバイオマーカー
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
JP6516925B2 (ja) 2015-09-09 2019-05-22 ノバルティス アーゲー 胸腺間質性リンパ球新生因子（ｔｓｌｐ）結合性抗体および抗体を使用する方法
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
EP3708580B1 (en) 2015-09-23 2023-11-01 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
ES2809125T3 (es) 2015-09-23 2021-03-03 Bristol Myers Squibb Co Moléculas de armazón a base de fibronectina de unión a glipicano-3
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
TN2018000112A1 (en) 2015-10-29 2019-10-04 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
EP3373969A4 (en) 2015-11-12 2019-08-14 Siamab Therapeutics, Inc. GLYCANINTERAGING COMPOUNDS AND METHOD OF USE
US10711282B2 (en) 2015-11-23 2020-07-14 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
EA201891338A1 (ru) 2015-12-04 2018-12-28 Новартис Аг Композиции и способы для иммуноонкологии
ES2941640T3 (es) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
EP3389711A1 (en) 2015-12-18 2018-10-24 Novartis AG Antibodies targeting cd32b and methods of use thereof
EP3393504B1 (en) 2015-12-22 2025-09-24 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
SG11201805449PA (en) 2015-12-28 2018-07-30 Novartis Ag Methods of making chimeric antigen receptor -expressing cells
AU2016382512A1 (en) 2015-12-30 2018-07-12 Novartis Ag Immune effector cell therapies with enhanced efficacy
IL260369B2 (en) 2016-01-06 2024-03-01 Lonza Ag Inhibition of protein breakdown for improved production
AU2017207736A1 (en) 2016-01-11 2018-07-12 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for immune indications
CN116003593A (zh) 2016-01-11 2023-04-25 苏黎世大学 针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
CA3014842A1 (en) 2016-02-19 2017-08-24 Morphosys Ag Antibodies for il-17c
EP3419599A4 (en) 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
AU2017226955B2 (en) 2016-03-04 2023-03-16 Morphosys Ag Polypeptide library
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
AU2017230823A1 (en) 2016-03-10 2018-09-27 Lonza Ltd Customizable facility
US10689873B2 (en) 2016-03-10 2020-06-23 Lonza Ltd Customizable facility
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
JP6987072B2 (ja) 2016-03-10 2021-12-22 アクセレロン ファーマ インコーポレーテッド アクチビン２型受容体結合タンパク質及びその使用
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
JP7038353B2 (ja) 2016-04-13 2022-03-18 ヴィヴィア バイオテック，エス．エル エクスビボのｂｉｔｅ活性化ｔ細胞
CA3020808A1 (en) 2016-04-14 2017-10-19 Lonza Ltd Compositions and methods for the detection of host cell proteins
MY209117A (en) 2016-04-15 2025-06-23 Novartis Ag Compositions and methods for selective protein expression
US10954287B2 (en) 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
CN116217731B (zh) 2016-04-22 2025-12-30 艾科赛扬制药股份有限公司 Alk7结合蛋白及其用途
WO2017189724A1 (en) 2016-04-27 2017-11-02 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
MX2018013499A (es) 2016-05-03 2019-09-11 Lonza Ag Modulacion del metabolismo lipidico para la produccion de proteinas.
EP3452097A1 (en) 2016-05-04 2019-03-13 Navigo Proteins GmbH Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
US10464969B2 (en) 2016-05-05 2019-11-05 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
TWI826351B (zh) 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
SG11201810687SA (en) * 2016-06-03 2018-12-28 Janssen Biotech Inc Serum albumin-binding fibronectin type iii domains
EP3464351A1 (en) 2016-06-07 2019-04-10 Novartis AG Anti-c5 antibody for treating patients with complement c5 polymorphism
US10975409B2 (en) 2016-06-10 2021-04-13 Lonza Ltd Method for stabilizing proteins
EP3471759A1 (en) 2016-06-15 2019-04-24 Novartis AG Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
JP2019527540A (ja) 2016-06-21 2019-10-03 ヤンセン バイオテツク，インコーポレーテツド システイン操作フィブロネクチンｉｉｉ型ドメイン結合分子
US20190336504A1 (en) 2016-07-15 2019-11-07 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
BR112019001570A2 (pt) 2016-07-28 2019-07-09 Novartis Ag terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
US20190161542A1 (en) 2016-08-01 2019-05-30 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
WO2018026577A1 (en) 2016-08-02 2018-02-08 Lonza Ltd Customizable facility
WO2018029586A1 (en) 2016-08-07 2018-02-15 Novartis Ag Mrna-mediated immunization methods
MA45921A (fr) 2016-08-08 2019-06-19 Amgen Inc Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine.
SG11201901066UA (en) 2016-08-11 2019-03-28 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin-binding proteins
MA46236A (fr) 2016-09-14 2019-07-24 Janssen Biotech Inc Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes
CN109906232B (zh) 2016-09-23 2023-11-07 马伦戈治疗公司 包含λ轻链和κ轻链的多特异性抗体分子
EP3523331A1 (en) * 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
BR112019008345A8 (pt) 2016-10-25 2023-03-07 Inst Nat Sante Rech Med Anticorpos monoclonais ligados à isoforma transmembrana cd160
US20180245065A1 (en) 2016-11-01 2018-08-30 Novartis Ag Methods and compositions for enhancing gene editing
EP3538546B1 (en) 2016-11-14 2025-01-08 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
NZ754187A (en) 2016-12-14 2026-02-27 Janssen Biotech Inc Cd8a-binding fibronectin type iii domains
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
US10852271B2 (en) 2016-12-14 2020-12-01 Taiwan Semiconductor Manufacturing Co., Ltd. On-chip heater
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
CA3045592A1 (en) 2016-12-21 2018-06-28 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
CN110325211A (zh) 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
IL267538B2 (en) 2016-12-23 2024-05-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
WO2018127585A1 (en) 2017-01-06 2018-07-12 Txcell Monospecific regulatory t cell population with cytotoxicity for b cells
EP3346001A1 (en) 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
US10899844B2 (en) 2017-02-08 2021-01-26 Novartis Ag FGF21 mimetic antibodies and uses thereof
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
US11274160B2 (en) 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
KR102746901B1 (ko) 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
KR102653141B1 (ko) 2017-03-03 2024-04-01 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
CA3055200A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
WO2018175636A2 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
MX2019011599A (es) 2017-03-30 2019-12-19 Univ Queensland Moleculas quimericas y usos de las mismas.
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
US12134654B2 (en) 2017-04-19 2024-11-05 Marengo Therapeutics, Inc. Multispecific molecules and uses thereof
SG11201909708VA (en) 2017-04-21 2019-11-28 Mellitus Llc Methods and antibodies for diabetes-related applications
CA3059769A1 (en) 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
MX2019014450A (es) * 2017-05-31 2020-02-10 Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Agriculture And Agri Food Vacuna contra la enteritis necrotica en aves de corral.
JP2020522254A (ja) 2017-05-31 2020-07-30 エルスター セラピューティクス， インコーポレイテッド 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
JP7247110B2 (ja) 2017-06-05 2023-03-28 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗ｃｄ３抗体
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US12054733B2 (en) 2017-06-16 2024-08-06 Lonza Ltd Universal self-regulating mammalian cell line platform for the production of biologics
WO2018234438A1 (en) 2017-06-22 2018-12-27 Morphosys Ag Canine antibody libraries
WO2019018402A2 (en) 2017-07-17 2019-01-24 Janssen Biotech, Inc. ANTIGEN-BINDING REGIONS DIRECTED AGAINST FIBRONECTIN TYPE III DOMAINS AND METHODS OF USING THE SAME
EP3654991A1 (en) 2017-07-19 2020-05-27 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for infectious disease
US20200172867A1 (en) 2017-07-19 2020-06-04 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for cardiometabolic disease
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CA3076261A1 (en) 2017-09-19 2019-03-28 Admare Vintageco1 Investments Ltd. Anti-hla-a2 antibodies and methods of using the same
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
EP3684822A4 (en) 2017-09-20 2021-06-16 The University of British Columbia NEW ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
US20230203149A1 (en) 2017-09-25 2023-06-29 Morphosys Ag Treatment of atopic dermatitis
MX2020004185A (es) 2017-09-27 2021-01-08 Univ Southern California Nuevas plataformas para coestimulacion, nuevos diseños car y otras mejoras para terapia celular adoptiva.
EP3470429A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
CN111183159B (zh) 2017-10-10 2024-09-03 努玛治疗有限公司 靶向cd137的抗体及其使用方法
AU2018348430B2 (en) 2017-10-10 2025-09-04 Numab Therapeutics AG Antibodies targeting PDL1 and methods of use thereof
EP3470428A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof
JP7585034B2 (ja) 2017-10-18 2024-11-18 ノバルティス アーゲー 選択的タンパク質分解のための組成物及び方法
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
MX2020004229A (es) 2017-10-25 2020-07-22 Novartis Ag Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
SG11202004512XA (en) 2017-11-15 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
KR20200087236A (ko) 2017-11-22 2020-07-20 노파르티스 아게 항-인자 XI/XIa 항체에 대한 반전 결합제 및 이의 용도
JP7685835B2 (ja) 2017-12-01 2025-05-30 ノバルティス アーゲー ポリオーマウイルス中和抗体
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
TW201930591A (zh) 2018-01-08 2019-08-01 瑞士商諾華公司 用於與嵌合抗原受體療法併用之免疫增強rna
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US11965191B2 (en) 2018-01-18 2024-04-23 California Institute Of Technology Programmable protein circuits in living cells
EP3740231A4 (en) 2018-01-18 2022-03-23 California Institute of Technology PROGRAMMABLE PROTEIN CIRCUITS IN LIVING CELLS
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
CN116218782A (zh) 2018-02-02 2023-06-06 隆萨有限公司 细胞选择和修饰细胞代谢的方法
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US11680091B2 (en) 2018-02-23 2023-06-20 The University Of Chicago Methods and composition involving thermophilic fibronectin type III (FN3) monobodies
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
CN117003874A (zh) 2018-03-20 2023-11-07 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
EP3774879B1 (en) 2018-03-30 2026-01-28 Amgen Inc. C-terminal antibody variants
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
SG11202010116PA (en) 2018-04-13 2020-11-27 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3788138A1 (en) 2018-05-02 2021-03-10 Novartis AG Regulators of human pluripotent stem cells and uses thereof
KR20210013090A (ko) 2018-05-16 2021-02-03 모르포시스 아게 당단백질 vi를 표적으로 하는 항체
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US11932681B2 (en) 2018-05-31 2024-03-19 Novartis Ag Hepatitis B antibodies
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
MX2020012927A (es) 2018-06-01 2021-03-25 Univ Southern California Diversos dominios de enlace de antigenos, nuevas plataformas y otras mejoras para terapia celular.
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN119613548A (zh) 2018-06-13 2025-03-14 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
TW202014209A (zh) 2018-06-20 2020-04-16 瑞士商諾華公司 用於消融造血幹細胞之抗體藥物軛合物
TW202011995A (zh) 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN112399972B (zh) 2018-07-10 2024-02-06 国家医疗保健研究所 戊型肝炎病毒orf2i蛋白的表位
ES2970072T3 (es) 2018-07-10 2024-05-24 Inst Nat Sante Rech Med Anticuerpos que tienen especificidad por la proteína ORF2i del virus de la hepatitis E y usos de los mismos con fines de diagnóstico
JP7543246B2 (ja) 2018-07-13 2024-09-02 ロンザ リミテッド 内因性タンパク質のレベルを低下させることによって生物学的産物の産生を改善する方法
WO2020028616A1 (en) 2018-08-02 2020-02-06 Lonza Ltd Methods for manufacturing recombinant protein comprising a disulfide bond
WO2020030979A2 (en) 2018-08-10 2020-02-13 Sangamo Therapeutics France New car constructs comprising tnfr2 domains
US11453893B2 (en) 2018-08-30 2022-09-27 California Institute Of Technology RNA-based delivery systems with levels of control
EP3844180A4 (en) 2018-08-31 2022-07-20 California Institute of Technology Synthetic protein circuits detecting signal transducer activity
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
CA3109959A1 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
JP7465272B2 (ja) 2018-09-27 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
US10955379B2 (en) 2018-09-27 2021-03-23 Taiwan Semiconductor Manufacturing Co., Ltd. Differential sensing with BioFET sensors
EP3856779A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd22 chimeric antigen receptor (car) therapies
WO2020069409A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020070240A1 (en) 2018-10-04 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of mucosal inflammatory diseases
TWI839395B (zh) 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
EP3636320A1 (en) 2018-10-09 2020-04-15 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2020092617A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody conjugates comprising sting agonists
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
WO2020102565A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Systems and methods for nondestructive testing of gametes
JP2022513164A (ja) 2018-11-30 2022-02-07 セルラリティ インク． 胎盤由来同種ｃａｒ－ｔ細胞およびその使用
JP2022513708A (ja) 2018-12-05 2022-02-09 モルフォシス・アーゲー 多重特異性抗原結合分子
CN113194925B (zh) 2018-12-14 2025-03-07 莫佛塞斯公司 抗体制剂
MA54501A (fr) 2018-12-18 2021-10-27 Navigo Proteins Gmbh Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer
EP3898700A1 (en) 2018-12-18 2021-10-27 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
JP7607564B2 (ja) 2018-12-21 2024-12-27 ノバルティス アーゲー Ｐｍｅｌ１７に対する抗体及びその結合体
CN111349550B (zh) * 2018-12-24 2022-12-23 中粮生物科技股份有限公司 一种高通量发酵好氧菌种的装置和方法以及他们的应用
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020146627A1 (en) 2019-01-10 2020-07-16 California Institute Of Technology A synthetic system for tunable thresholding of protein signals
US12410260B2 (en) 2019-01-11 2025-09-09 The University Of North Carolina At Chapel Hill Highly modular biepitopic and bispecific CAR-T cells for cancer immunotherapy
JP7525499B2 (ja) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
WO2020172601A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
AU2020226904B2 (en) 2019-02-21 2025-05-01 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
EP3927745A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
MA55285A (fr) 2019-03-14 2022-01-19 Morphosys Ag Anticorps ciblant c5ar
EP3938394A1 (en) 2019-03-15 2022-01-19 MorphoSys AG Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
JP7286796B2 (ja) 2019-04-03 2023-06-05 プレシジョン バイオサイエンシズ，インク． マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞
WO2020206231A1 (en) 2019-04-05 2020-10-08 Precision Biosciences, Inc. Methods of preparing populations of genetically-modified immune cells
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
AU2020257748A1 (en) 2019-04-19 2021-11-18 Chugai Seiyaku Kabushiki Kaisha Chimeric receptor recognizing modification site of antibody
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
EP3962527A4 (en) 2019-04-30 2023-11-01 Senti Biosciences, Inc. CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
MX2021013101A (es) 2019-05-03 2022-01-04 Morphosys Ag Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk.
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
KR20220024106A (ko) 2019-05-20 2022-03-03 노파르티스 아게 Mcl-1 억제제 항체-약물 접합체 및 사용 방법
KR20220010527A (ko) 2019-05-20 2022-01-25 노파르티스 아게 친수성 기를 포함하는 링커를 갖는 항체 약물 콘쥬게이트
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
CN113966224A (zh) 2019-06-04 2022-01-21 Ra制药公司 采用补体抑制剂的炎性疾病治疗
EA202193345A1 (ru) 2019-06-12 2022-03-16 Новартис Аг Антитела к рецептору-1 натрийуретического пептида и способы их применения
KR20220024729A (ko) 2019-06-24 2022-03-03 노파르티스 아게 B-세포 성숙 항원을 표적으로 하는 다중특이성 항체에 대한 투여 요법 및 병용 요법
CN112239507A (zh) 2019-07-17 2021-01-19 鸿运华宁（杭州）生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
EP4004216A1 (en) 2019-07-25 2022-06-01 Precision BioSciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
EP4014050A1 (en) 2019-08-12 2022-06-22 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
AU2020333851A1 (en) 2019-08-20 2022-03-31 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
US11787840B2 (en) 2019-08-23 2023-10-17 The United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating and preventing autoimmune induced cardiac long QT syndrome
US12460009B2 (en) 2019-09-04 2025-11-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Monoclonal antibodies specific for IL20-Rb, encoding nucleic acids thereof and methods of use thereof to treat bacterial-induced exacerbation of chronic obstructive pulmonary disease
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP3800201A1 (en) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h stimulation enhances nk cell killing activities
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
EP3808766A1 (en) 2019-10-15 2021-04-21 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
US10984211B1 (en) 2019-10-18 2021-04-20 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device with bioFET and biometric sensors
WO2021087305A1 (en) 2019-10-30 2021-05-06 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
TWI865644B (zh) 2019-10-31 2024-12-11 德商莫菲西斯公司 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
US20210130461A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
EP4058583A1 (en) 2019-11-14 2022-09-21 Lonza Ltd. Methods of cell selection
KR20220115569A (ko) 2019-11-18 2022-08-17 얀센 바이오테크 인코포레이티드 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors cd19 and cd22 and their uses
PH12022551291A1 (en) 2019-11-26 2023-11-20 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof
MX2022006704A (es) 2019-12-04 2022-11-09 Celularity Inc Linfocitos car-t alogenicos derivados de placenta y usos de estos.
EP4069285A1 (en) 2019-12-06 2022-10-12 Precision BioSciences, Inc. Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells
US12162953B2 (en) 2019-12-06 2024-12-10 Yale University Enhanced targeting platform
EP4073115A1 (en) 2019-12-09 2022-10-19 Novartis AG Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
US12577324B2 (en) 2019-12-09 2026-03-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity to HER4 and uses thereof
WO2021127353A1 (en) 2019-12-18 2021-06-24 Aro Biotherapeutics Company Serum albumin-binding fibronectin type iii domains and uses thereof
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
EP4104187A1 (en) 2020-02-14 2022-12-21 Novartis AG Method of predicting response to chimeric antigen receptor therapy
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
EP4111168A1 (en) 2020-02-25 2023-01-04 Becton Dickinson and Company Bi-specific probes to enable the use of single-cell samples as single color compensation control
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
KR20220146530A (ko) 2020-02-27 2022-11-01 노파르티스 아게 키메라 항원 수용체-발현 세포의 제조 방법
JP2023518049A (ja) 2020-03-16 2023-04-27 ユニバーシティ オブ サザン カリフォルニア 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
CA3172120A1 (en) 2020-03-20 2021-09-23 Inserm (Institut De La Sante Et De La Recherche Medicale) Chimeric antigen receptor specific for human cd45rc and uses thereof
CN116249549A (zh) 2020-03-27 2023-06-09 诺华股份有限公司 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
US12215170B2 (en) 2020-04-07 2025-02-04 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
EP4136228A4 (en) 2020-04-15 2024-09-11 California Institute of Technology THERMAL REGULATION OF T-CELL IMMUNOTHERAPY BY MOLECULAR AND PHYSICAL ACTUATION
MX2022012752A (es) 2020-04-15 2023-01-16 Voyager Therapeutics Inc Compuestos de union a tau.
GB2612450A (en) 2020-04-24 2023-05-03 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
KR20230022411A (ko) 2020-05-12 2023-02-15 라이엘 이뮤노파마, 인크. 키메라 항원 수용체 스페이서
JP2023525053A (ja) 2020-05-12 2023-06-14 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 皮膚ｔ細胞リンパ腫及びｔｆｈ由来リンパ腫を処置する新しい方法
KR20230012592A (ko) 2020-05-19 2023-01-26 르 라보레또레 쎄르비에르 파라-아미노-벤질 링커, 이의 제조 방법 및 컨쥬게이트에서의 이의 용도
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
WO2021252804A1 (en) 2020-06-12 2021-12-16 Nkarta, Inc. Genetically modified natural killer cells for cd70-directed cancer immunotherapy
US20230014026A1 (en) 2020-06-22 2023-01-19 Morphosys Ag Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
PH12023550015A1 (en) 2020-07-16 2024-03-11 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2022035793A1 (en) 2020-08-10 2022-02-17 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
US20230302155A1 (en) 2020-08-21 2023-09-28 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
AU2021331076A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
KR20230074487A (ko) 2020-08-26 2023-05-30 마렝고 테라퓨틱스, 인크. Trbc1 또는 trbc2를 검출하는 방법
CA3190755A1 (en) 2020-08-26 2022-03-03 Andreas Loew Multifunctional molecules that bind to calreticulin and uses thereof
US11999964B2 (en) 2020-08-28 2024-06-04 California Institute Of Technology Synthetic mammalian signaling circuits for robust cell population control
JP7788106B2 (ja) * 2020-08-31 2025-12-18 国立大学法人東海国立大学機構 フィブロネクチンｉｉｉ型ドメイン骨格を含むポリペプチド
US20230357398A1 (en) 2020-09-24 2023-11-09 Morphosys Ag Novel human antibodies binding to human cd3 epsilon
WO2022076547A1 (en) 2020-10-07 2022-04-14 Precision Biosciences, Inc. Lipid nanoparticle compositions
WO2022097090A1 (en) 2020-11-05 2022-05-12 Novartis Ag Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
US20250215081A1 (en) 2020-11-06 2025-07-03 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
JP2023547499A (ja) 2020-11-06 2023-11-10 ノバルティス アーゲー 抗体Ｆｃ変異体
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
KR20230107617A (ko) 2020-11-13 2023-07-17 노파르티스 아게 키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
CA3200858A1 (en) 2020-11-24 2022-06-02 Novartis Ag Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
AU2021386367A1 (en) 2020-11-24 2023-06-22 Les Laboratoires Servier Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
US20220184208A1 (en) 2020-12-04 2022-06-16 Morphosys Ag Anti-cd19 combination therapy
EP4259661A1 (en) 2020-12-14 2023-10-18 Novartis AG Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
EP4263599A1 (en) 2020-12-16 2023-10-25 Voyager Therapeutics, Inc. Tau binding compounds
WO2022165111A1 (en) 2021-01-28 2022-08-04 Precision Biosciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
WO2022171736A1 (en) 2021-02-10 2022-08-18 Limagrain Europe Multiplex targeted recombinations for trait introgression applications
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CN115141276A (zh) 2021-03-31 2022-10-04 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
BR112023021318A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Conjugados de domínio fn3-sirna e usos dos mesmos
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
CA3235132A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
TW202307210A (zh) 2021-06-01 2023-02-16 瑞士商諾華公司 Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
EP4355352A1 (en) 2021-06-18 2024-04-24 advanceCOR GmbH Use of a pharmaceutical composition
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US11958899B2 (en) 2021-07-13 2024-04-16 Mabwell Therapeutics Inc. Anti-C1s antibodies and uses thereof
CA3227537A1 (en) 2021-07-27 2023-02-02 Morphosys Ag Combinations of antigen binding molecules
JP2024531364A (ja) 2021-08-20 2024-08-29 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
GB202113674D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
GB202113673D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
WO2023064872A1 (en) 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
JP2024540196A (ja) 2021-10-27 2024-10-31 グラニット バイオ アーゲー Ｃｃｒ２を標的とする抗体
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
US20250009800A1 (en) 2021-11-16 2025-01-09 Precision Biosciences, Inc. Methods for cancer immunotherapy
EP4436982A1 (en) 2021-11-24 2024-10-02 Novartis AG Modulators of adeno-associated virus transduction and uses thereof
US20250041417A1 (en) 2021-12-10 2025-02-06 Precision Biosciences, Inc. Methods for cancer immunotherapy
EP4453224A1 (en) 2021-12-21 2024-10-30 Universität Zürich Adenoviral vectors
EP4473010A1 (en) 2022-02-01 2024-12-11 Institut National de la Santé et de la Recherche Médicale (INSERM) Method for diagnosing collagen degradatation associated disease
IL314634A (en) 2022-02-18 2024-09-01 Adivo Gmbh Feline Antibody Library
JP2025508472A (ja) 2022-02-25 2025-03-26 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） メタロプロテアーゼによるｃｄ９５ｌの切断を阻止するための抗体
KR20240155353A (ko) 2022-03-11 2024-10-28 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인쎄름) B 및 t 세포의 특이적 재프로그래밍을 위한 핵산 시스템 및 이의 용도
US20250206819A1 (en) 2022-03-22 2025-06-26 Morphosys Ag Deimmunized antibodies specific for cd3
US20250215452A1 (en) 2022-03-25 2025-07-03 Universität Zürich Adenoviral Mediated Targeting of Activated Immune Cells
WO2023187657A1 (en) 2022-03-30 2023-10-05 Novartis Ag Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
TW202340259A (zh) 2022-04-14 2023-10-16 瑞士商諾華公司 抗cd19藥劑之劑量方案及其用途
US20250353883A1 (en) 2022-05-06 2025-11-20 Novartis Ag Novel recombinant aav vp2 fusion polypeptides
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CN120787162A (zh) 2022-05-20 2025-10-14 诺华股份有限公司 抗肿瘤化合物的抗体-药物缀合物及其使用方法
IL317102A (en) 2022-05-20 2025-01-01 Novartis Ag EPHA2 BCL-XL inhibitor antibody-drug conjugates and methods of using them
US20250339547A1 (en) 2022-05-20 2025-11-06 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
EP4543473A1 (en) 2022-06-22 2025-04-30 Voyager Therapeutics, Inc. Tau binding compounds
KR20250034296A (ko) 2022-07-07 2025-03-11 씨메이오 테라퓨틱스 아게 Cd117을 표적화하는 항체
US20260078376A1 (en) 2022-08-26 2026-03-19 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer
US20260061078A1 (en) 2022-08-31 2026-03-05 Universität Zürich Adenoviral-Based In Situ Delivery of Bispecific T Cell Engagers
JP2025531814A (ja) 2022-09-08 2025-09-25 ジーマックス バイオファーム エルエルシー Ｇｉｐｒ抗体、ｆｇｆ２１との融合タンパク質、その医薬組成物及びその使用
EP4584291A1 (en) 2022-09-08 2025-07-16 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
EP4587047A1 (en) 2022-09-15 2025-07-23 Novartis AG Treatment of autoimmune disorders using chimeric antigen receptor therapy
CA3266790A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. TAU PROTEIN BINDING COMPOUNDS
US20260103541A1 (en) 2022-10-07 2026-04-16 Universität Zürich Paracrine Adenoviral Delivery of Biomolecules
AU2023369998A1 (en) 2022-10-24 2025-01-23 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists
WO2024099990A1 (en) 2022-11-07 2024-05-16 Leibniz-Institut Für Immuntherapie (Lit) TGF-ß SWITCH RECEPTOR CAR T CELLS
IL320985A (en) 2022-11-28 2025-07-01 Novartis Ag PCTA derivatives, their conjugates and their uses
KR20250114116A (ko) 2022-12-01 2025-07-28 제너레이션 바이오 컴퍼니 세포 표적화를 위한 스텔스 지질 나노입자 조성물
JP2026500540A (ja) 2022-12-23 2026-01-07 シメイオ セラピューティクス アーゲー Ｃｄ４５を標的とする抗体
WO2024148167A1 (en) 2023-01-05 2024-07-11 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene
CN120513256A (zh) 2023-01-20 2025-08-19 迈威(美国)生物治疗有限公司 抗淀粉样蛋白β原纤丝/低聚物抗体和其用途
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
AU2024234194A1 (en) 2023-03-10 2025-08-07 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
EP4688848A1 (en) 2023-03-27 2026-02-11 Zoetis Services LLC Anti-canine pd-l1 antibodies
WO2024236163A1 (en) 2023-05-17 2024-11-21 Morphosys Ag T cell receptor beta constant region 2 (trbc2) antibodies
WO2024236167A1 (en) 2023-05-17 2024-11-21 Morphosys Ag Il-13 receptor alpha 2 binding polypeptides
WO2024245988A1 (en) 2023-05-29 2024-12-05 Granite Bio Ag Antibodies targeting ccr2
KR20260019463A (ko) 2023-06-01 2026-02-10 피에르 파브르 메디카먼트 종양 및 전이의 치료를 위한 침묵화된 항체 기반의 항-met 구조물
WO2024261027A1 (en) 2023-06-19 2024-12-26 Vector Biopharma Ag Il-7-retargeting of adenoviruses for cell specific infection
WO2025003511A1 (en) 2023-06-30 2025-01-02 Morphosys Ag Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
CN121712801A (zh) 2023-08-14 2026-03-20 莫佛塞斯有限责任公司 包含空间位阻部分的CyCAT半体分子
WO2025061682A1 (en) 2023-09-21 2025-03-27 Universität Zürich Adenoviral targeting of dendritic cells
WO2025068454A1 (en) 2023-09-28 2025-04-03 Sixpeaks Bio Ag Antibodies targeting actriia and actriib
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025087681A1 (en) 2023-10-26 2025-05-01 Morphosys Ag Bispecific antibodies against cd3 and cd20
CN117503754A (zh) * 2023-11-07 2024-02-06 南开沧州渤海新区绿色化工研究有限公司 磺化硫桥偶氮杯芳烃及其与锰的配合物在清除活性氧中的应用
TW202540186A (zh) 2023-11-22 2025-10-16 瑞士商諾華公司 抗ｃｄ７抗體藥物結合物及其使用方法
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
WO2025109043A2 (en) 2023-11-22 2025-05-30 Institut National de la Santé et de la Recherche Médicale Use of neutralizing anti-agr2 antibodies for preventing resistance to chemotherapy
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025129085A1 (en) 2023-12-15 2025-06-19 Port Therapeutics, Inc. Use of thermal bioswitches in aav-based gene therapy
WO2025129120A2 (en) 2023-12-15 2025-06-19 Port Therapeutics, Inc. Use of thermal bioswitches for treating autoimmune diseases
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025247917A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 AND ANTI-IFN-ω1 MONOCLONAL ANTIBODIES
WO2025247924A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 MONOCLONAL ANTIBODIES
WO2025247918A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 MONOCLONAL ANTIBODIES
WO2025247913A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale Anti-ifn-omega1 monoclonal antibodies
WO2025250739A1 (en) 2024-05-31 2025-12-04 Janssen Biotech, Inc. Chimeric antigen receptor with spacer domains derived from human igg
WO2025259600A2 (en) 2024-06-10 2025-12-18 University Of Rochester Brain protein targets for the treatment of migraine
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2026062582A1 (en) 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies
WO2026062585A1 (en) 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963355A (en) * 1986-06-23 1990-10-16 Igen, Inc. Production of antibody catalysts
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5258289A (en) 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
AU6235294A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
ATE210724T1 (de) 1993-04-09 2001-12-15 Catalytic Antibodies Inc Selektion von genen katalytischer antikörper
JPH10507341A (ja) 1994-03-30 1998-07-21 アイジェン， インコーポレイテッド ファージ技術を用いる触媒性抗体の単離および産生
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
US7115396B2 (en) * 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6391855B1 (en) * 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
CA2416219C (en) * 2000-07-11 2016-10-11 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US7598352B2 (en) * 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
WO2004019878A2 (en) 2002-08-27 2004-03-11 Compound Therapeutics, Inc. Adzymes and uses thereof
US20040259155A1 (en) * 2002-09-30 2004-12-23 Compound Therapeutics, Inc. Methods of engineering spatially conserved motifs in polypeptides
CN1946417A (zh) 2003-12-05 2007-04-11 阿德内克休斯治疗公司 2型血管内皮生长因子受体的抑制剂

Also Published As

Publication number Publication date
US8106162B2 (en) 2012-01-31
EP0985039A2 (en) 2000-03-15
CA2293632A1 (en) 1998-12-17
US7858090B2 (en) 2010-12-28
US20060240018A1 (en) 2006-10-26
US20030170753A1 (en) 2003-09-11
DE69839147T2 (de) 2009-02-19
US20090270597A1 (en) 2009-10-29
WO1998056915A3 (en) 1999-03-04
EP0985039B1 (en) 2008-02-20
US6703199B1 (en) 2004-03-09
US20030134386A1 (en) 2003-07-17
US6673901B2 (en) 2004-01-06
US20060257953A1 (en) 2006-11-16
US7078490B2 (en) 2006-07-18
EP1958962A2 (en) 2008-08-20
EP2380906A2 (en) 2011-10-26
US20020019517A1 (en) 2002-02-14
US8062858B2 (en) 2011-11-22
AU729035B2 (en) 2001-01-25
AU7959698A (en) 1998-12-30
US9127090B2 (en) 2015-09-08
DE69839147D1 (de) 2008-04-03
WO1998056915A2 (en) 1998-12-17
US6462189B1 (en) 2002-10-08
ATE386802T1 (de) 2008-03-15
US7981620B2 (en) 2011-07-19
JP3614866B2 (ja) 2005-01-26
US7119171B2 (en) 2006-10-10
CA2293632C (en) 2011-11-29
US20100099168A1 (en) 2010-04-22
US7153661B2 (en) 2006-12-26
ES2301198T3 (es) 2008-06-16
EP1958962A3 (en) 2013-05-01
US20030108948A1 (en) 2003-06-12
JP2001500531A (ja) 2001-01-16
US20120135516A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
DK0985039T3 (da) Kunstige antistof-polypeptider
WO2002004523A3 (en) Artificial antibody polypeptides
ATE110773T1 (de) Verfahren zur züchtung rekombinanter zellen.
ATE145239T1 (de) Rns-katalysator zur spaltung von spezifischen rns-sequenzen
FI883082A0 (fi) Konstruering av syntetisk dna och dess anvaendning i syntes av stora polypeptider.
WO2000006726A3 (en) Delta-related polypeptides
ATE152124T1 (de) Wachstumsfaktor aus parenchymalen lebenszellen, dafür kodierendes gen, verfahren zur herstellung dieses faktors und transformanten
RU2005136013A (ru) Фосфодиэстераза 8а
EP0821064A3 (en) Recombinant fructosyl amino acid oxidase
EP0236978A3 (en) Production of factor xiiia by gene technology
DE3486350D1 (de) VERFAHREN ZUR ISOLIERUNG EINES PROTEINS AUS EINER DIESES PROTEIN ENTHALTENDEN MISCHUNG UNTER VERWENDUNG EINES KONFORMATIONSSPEZIFISCHEN ANTIKöRPERS.
ATE152481T1 (de) Neue polypeptide, dna-sequenzen, die deren expression erlauben, verfahren zur vorbereitung und verwendung
DE69736389T8 (de) Proteine mit zellulase-aktivitäten und prozess für ihre herstellung
DE69430975D1 (de) Verfahren zur Herstellung von Proteinen
EP0333587B1 (en) Method for purifying and isolating carboxyl-terminal peptides
EP1705185A3 (en) Reagent for the diagnosis of rheumatoid arthritis
ATE102994T1 (de) Verfahren zur herstellung von proteinen.
ATE345382T1 (de) 2,6-beta-d-fruktanhydrolase enzym und verfahren zu dessen verwendung
EP0745674A3 (en) Helicobacter polypeptides, their production and use
WO1999029724A3 (en) Dna encoding pasteurella multocida outer membrane protein
US6762041B2 (en) Method for isotope labeling of protein with enzyme
EP0289187A3 (en) Vinyl substituted radiohalogen conjugates for protein labeling
WO1999023228B1 (en) Svph1-26 dna and polypeptides
DE69634297D1 (de) Verfahren zur verlängerung der expression eines interessierenden gens unter verwendung von löslichen ctla4 molekülen
ATE245695T1 (de) Polypeptidproduktion